Welcome to our dedicated page for Halozyme Thrp SEC filings (Ticker: HALO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Halozyme Therapeutics, Inc. (HALO) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biopharmaceutical company, Halozyme uses Forms 10-K, 10-Q and 8-K to report on its drug delivery business, collaborations, financing activities and governance matters.
Through current reports on Form 8-K, Halozyme discloses material events such as the issuance of convertible senior notes due 2031 and 2032, amendments to its revolving credit facility, entry into and completion of the Elektrofi acquisition, significant collaboration agreements, and executive appointments or transitions. These filings often include details on note terms, capped call transactions, credit covenants and merger conditions that are not fully described in press releases.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (not reproduced here but referenced in 8-Ks) typically contain broader discussions of Halozyme’s ENHANZE, Hypercon and MDASE technology portfolios, risk factors, royalty and collaboration structures, and overall financial condition. Investors use these filings to understand how platform licensing, proprietary products and acquisitions contribute to the company’s long-term strategy.
Stock Titan enhances this information with AI-powered summaries that highlight key terms in lengthy documents, such as conversion conditions for the company’s notes, leverage and coverage ratios in its credit agreement, and the main obligations and covenants in merger contracts. Users can also review disclosures related to executive compensation arrangements, transition agreements and other governance topics reported under Item 5.02 of Form 8-K.
By combining real-time updates from EDGAR with AI-generated explanations, the Halozyme filings page helps readers quickly locate and interpret the sections of 10-Ks, 10-Qs, 8-Ks and related exhibits that are most relevant to their analysis of HALO stock.
Halozyme Therapeutics (HALO) President and CEO Helen Torley executed a series of pre-planned transactions under a Rule 10b5-1 trading plan established on March 21, 2025. The transactions occurred over three consecutive days:
- June 20, 2025: Exercised 20,000 options at $8.11 and sold 20,000 shares at avg. $52.96
- June 23, 2025: Exercised 20,000 options at $8.11 and sold 20,000 shares at avg. $52.57
- June 24, 2025: Exercised 20,000 options at $8.11 and sold 20,000 shares (4,489 at avg. $53.11 and 15,511 at avg. $53.91)
Following these transactions, Torley holds 733,719 shares directly and 316,569 options at $8.11 strike price expiring February 3, 2026. The options were originally granted in 2016 with a 4-year vesting schedule. All transactions were executed under a pre-established 10b5-1 trading plan, demonstrating compliance with insider trading regulations.